This company has been marked as potentially delisted and may not be actively trading. resTORbio (TORC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TORC vs. VIRI, WHWK, ELYM, OSTX, ATNM, NBRV, AADI, EGRX, PYRGF, and NNVCShould you be buying resTORbio stock or one of its competitors? The main competitors of resTORbio include Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), Eliem Therapeutics (ELYM), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), Nabriva Therapeutics (NBRV), Aadi Bioscience (AADI), Eagle Pharmaceuticals (EGRX), PyroGenesis Canada (PYRGF), and NanoViricides (NNVC). resTORbio vs. Its Competitors Virios Therapeutics Whitehawk Therapeutics Eliem Therapeutics OS Therapies Actinium Pharmaceuticals Nabriva Therapeutics Aadi Bioscience Eagle Pharmaceuticals PyroGenesis Canada NanoViricides resTORbio (NASDAQ:TORC) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Do analysts rate TORC or VIRI? Virios Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 2.25%. Given Virios Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Virios Therapeutics is more favorable than resTORbio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score resTORbio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virios Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation & earnings, TORC or VIRI? Virios Therapeutics is trading at a lower price-to-earnings ratio than resTORbio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioresTORbioN/AN/A-$82.74M-$2.41-0.34Virios TherapeuticsN/AN/A-$5.30M-$0.27-18.11 Does the media refer more to TORC or VIRI? In the previous week, resTORbio's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score. Company Overall Sentiment resTORbio Neutral Virios Therapeutics Neutral Which has more volatility & risk, TORC or VIRI? resTORbio has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Do insiders and institutionals believe in TORC or VIRI? 46.2% of resTORbio shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 11.8% of resTORbio shares are held by insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is TORC or VIRI more profitable? resTORbio's return on equity of -78.12% beat Virios Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets resTORbioN/A -78.12% -71.63% Virios Therapeutics N/A -130.33%-115.00% SummaryresTORbio and Virios Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TORC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TORC vs. The Competition Export to ExcelMetricresTORbioPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.54M$736.37M$5.84B$10.14BDividend YieldN/A4.84%5.68%4.60%P/E Ratio-0.451.1775.4125.98Price / SalesN/A26.64515.81181.13Price / CashN/A19.5637.5660.44Price / Book0.366.6812.156.29Net Income-$82.74M-$4.13M$3.29B$271.07M resTORbio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TORCresTORbioN/A$0.81-8.1%N/A-47.0%$29.54MN/A-0.45N/AGap DownVIRIVirios TherapeuticsN/A$4.83-1.4%$5.00+3.5%+2,410.3%$93.02MN/A-17.895WHWKWhitehawk Therapeutics1.1859 of 5 stars$1.83+1.7%N/AN/A$86.25M$25.98M-30.5021ELYMEliem TherapeuticsN/A$2.47+3.3%N/A-73.4%$73.49MN/A-4.669News CoverageOSTXOS Therapies2.074 of 5 stars$2.20+0.5%$18.00+718.2%-34.6%$68.99MN/A-2.76N/AAnalyst ForecastATNMActinium Pharmaceuticals3.0645 of 5 stars$1.62+0.9%$4.50+178.6%-12.4%$50.38MN/A-1.1630Short Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070AADIAadi BioscienceN/A$1.80+0.6%N/A+10.6%$44.46M$25.07M-0.7940EGRXEagle PharmaceuticalsN/A$3.21flatN/A-25.5%$41.69M$257.55M0.00100Gap DownPYRGFPyroGenesis CanadaN/A$0.18-0.5%N/A-67.9%$32.84M$9.14M-2.9290Gap UpNNVCNanoViricides0.1492 of 5 stars$1.44-1.7%N/A-9.4%$23.06MN/A-1.9920Short Interest ↑ Related Companies and Tools Related Companies Virios Therapeutics Alternatives Whitehawk Therapeutics Alternatives Eliem Therapeutics Alternatives OS Therapies Alternatives Actinium Pharmaceuticals Alternatives Nabriva Therapeutics Alternatives Aadi Bioscience Alternatives Eagle Pharmaceuticals Alternatives PyroGenesis Canada Alternatives NanoViricides Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TORC) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share resTORbio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TORC Stock Alerts